Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 836826 plus GemOx versus rituximab plus GemOx in relapsed/refractory diffuse large B-cell lymphoma
2014-004794-16Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of BI 836826 in diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) (3 arms), sponsored by Boehringer Ingelheim. Started Sep 2015; status: completed.
02
Drugs
BI 836826
03
Conditions
diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)
Beyond the preview
Go deeper on 2014-004794-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004794-16.